首页>
外国专利>
GENE SIGNATURES AND METHOD FOR PREDICTING RESPONSE TO PD-1 ANTAGONISTS AND CTLA-4 ANTAGONISTS, AND COMBINATION THEREOF
GENE SIGNATURES AND METHOD FOR PREDICTING RESPONSE TO PD-1 ANTAGONISTS AND CTLA-4 ANTAGONISTS, AND COMBINATION THEREOF
展开▼
机译:预测PD-1拮抗剂和CTLA-4拮抗剂反应的基因标志,方法及其组合
展开▼
页面导航
摘要
著录项
相似文献
摘要
The present invention relates to the field of cancer, more particularly to the field of immunotherapy and gene signatures. Provided are two specific and distinct gene signatures, namely a Response Immune Signal (RIS) gene signature and a Stromal Immune Signal (SIS) gene signature, which can be used as biomarkers to accurately predict the response of a cancer subject to treatment with a PD-1 antagonist (e.g., PD-1 antibody) and/or a CTLA-4 antagonist (e.g., CTLA-4 antibody). In particular, it was found that the RIS and SIS gene signatures of the invention may be used in combination to predict the response of a cancer subject to treatment with a combination therapy consisting of a PD-1 antagonist (e.g., PD-1 antibody) and a CTLA-4 antagonist (e.g., CTLA-4 antibody). The gene signatures of the invention may be advantageously used in methods for treating cancer, such as melanoma, and to help devise treatment strategies best suited to individual patients (e.g., to achieve personalized therapy, and spare patients from undesired side effects, e.g., toxicity).
展开▼